Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 38

Sort by

Sort Order Select

Journal Articles

Deciphering the Heterogeneity of Acute Myeloid Leukemia through Chromatin Accessibility Profiling

Blood (2024) 144 (Supplement 1): 639.

https://doi.org/10.1182/blood-2024-200415

Published: 2024

Journal Articles

Resistance to FLT3 Inhibitors in FLT3-Mutated AML Is Associated with CD45RA + CD200 - leukemic Cells and Can be Overcome By Combination with SMAC Mimetics

Blood (2024) 144 (Supplement 1): 1565.

https://doi.org/10.1182/blood-2024-200093

Published: 2024

Journal Articles

Targeting Mitochondrial Apoptotic Priming State to Personalize Therapy for Relapsed Acute Myeloid Leukemia

Blood (2023) 142 (Supplement 1): 48.

https://doi.org/10.1182/blood-2023-189156

Published: 2023

Journal Articles

Computational Approach Based on Independent Drug Action Identifies Clinically Relevant Combinations for Acute Myeloid Leukemia

Xiao Xian Lin, Vedant Sandhu, Christopher A. Eide, Stephen E. Kurtz, Disha Malani, Tom Erkers, Olli Kallioniemi, Jeffrey W Tyner, Shruti Bhatt

Blood (2023) 142 (Supplement 1): 5015.

https://doi.org/10.1182/blood-2023-188731

Published: 2023

Journal Articles

Data-Driven Molecular Hallmarks of Acute Myeloid Leukemia: Biological, Prognostic and Therapeutic Implications

Tom Erkers, Francesco Marabita, Nona Struyf, Mattias Vesterlund, Tojo James, Cornelia Arnroth, Anna Bohlin, Sofia Bengtzén, Albin Österroos, Matthias Stahl, Rozbeh Jafari, Lukas Orre, Yudi Pawitan, Brinton Seashore-Ludlow, Janne Lehtiö, Sören Lehmann, Päivi Östling, Olli Kallioniemi

Blood (2022) 140 (Supplement 1): 6299.

https://doi.org/10.1182/blood-2022-163046

Published: 2022

Journal Articles

Comparison of Data from Fresh and Frozen AML Samples for Functional Drug Testing

Nona Struyf, Cornelia Arnroth, Stephanie Sunandar, Anna Bohlin, Sofia Bengtzén, Sören Lehmann, Olli Kallioniemi, Päivi Östling, Brinton Seashore-Ludlow, Tom Erkers

Blood (2022) 140 (Supplement 1): 6290.

https://doi.org/10.1182/blood-2022-157262

Published: 2022

Journal Articles

High-Throughput Functional Ex-Vivo Drug Testing and Multi-Omics Profiling in Patients with Acute Myeloid Leukemia

Tom Erkers, PhD, Brinton Seashore-Ludlow, Nona Struyf, Francesco Marabita, Tojo James, Disha Malani, Mattias Vesterlund, Matthias Stalhl, Yudi Pawitan, Sören Lehmann, MD PhD, Päivi Östling, Janne Lehtiö, Olli Kallioniemi

Blood (2019) 134 (Supplement_1): 4641.

https://doi.org/10.1182/blood-2019-124332

Published: 2019

Journal Articles

Predictive Response Biomarkers for BET Inhibitors in AML

Joseph J Saad, MSc, BSc, Juho Miettinen, PhD, Dimitrios Tsallos, BSc(Hons),MSc, Samuli Eldfors, PhD, Mika Kontro, MD, Krister Wennerberg, PhD, Olli Kallioniemi, MD PhD, Kimmo Porkka, MD PhD, Jing Tang, PhD, Caroline A Heckman, PhD

Blood (2018) 132 (Supplement 1): 2749.

https://doi.org/10.1182/blood-2018-99-118363

Published: 2018

Journal Articles

Comparative Analysis of Independent Ex Vivo functional Drug Screens Identifies Predictive Biomarkers of BCL-2 Inhibitor Response in AML

Brian S. White, PhD, Suleiman A. Khan, PhD, Muhammad Ammad-ud-din, PhD, Swapnil Potdar, MSc, Mike J Mason, PhD, Cristina E. Tognon, PhD, Brian J. Druker, MD, Caroline A Heckman, PhD, Olli Kallioniemi, MD PhD, Stephen E Kurtz, PhD, Kimmo Porkka, MD PhD, Jeffrey W. Tyner, PhD, Tero Aittokallio, PhD, Krister Wennerberg, PhD, Justin Guinney, PhD

Blood (2018) 132 (Supplement 1): 2763.

https://doi.org/10.1182/blood-2018-99-111916

Published: 2018

Journal Articles

Multi-Parametric Single Cell Profiling Defines Distinct Drug Responses in Healthy Hematological Cell Lineages That Are Retained in Corresponding Malignant Cell Types

Muntasir M Majumder, MSc, BPharm, Maija Leppä, MSc(Tech), Monica Hellesoy, PhD, Paul Dowling, BSc, PhD, Alina Malyutina, Despina Bazou, BSc, MSc, PhD, Emma Irene Andersson, MSc, Alun Parsons, Jing Tang, PhD, Olli Kallioniemi, MD PhD, Satu Mustjoki, MDPhD, Peter O'Gorman, MD PhD FRCP, FRCPath, Krister Wennerberg, PhD, Kimmo Porkka, MD PhD, Bjorn Gjertsen, MD PhD, Caroline A Heckman, PhD

Blood (2018) 132 (Supplement 1): 264.

https://doi.org/10.1182/blood-2018-99-118242

Published: 2018

Journal Articles

Quantitative Multiplex Immunohistochemistry Identifies Immunosuppression in the AML Bone Marrow and NK-Cells As Prognostic Biomarker in Intermediate-Risk Patients

Oscar Brück, MD, Olli Dufva, Sami Blom, MSc, Riku Turkki, MSc, Mette Ilander, PhD, Sanna M. Siitonen, MD PhD, Panu Kovanen, MD PhD, Celine Pallaud, PhD, Pedro Marques Ramos, PhD, Hanna Lähteenmäki, Katja Välimäki, Antonio Ribeiro, BSc, Olli Kallioniemi, MD PhD, Kimmo Porkka, MD PhD, Teijo Pellinen, PhD, Satu Mustjoki, MD PhD

Blood (2018) 132 (Supplement 1): 2774.

https://doi.org/10.1182/blood-2018-99-116628

Published: 2018

Journal Articles

Gene-Drug Interactions in AML Patients Identified By RNA Sequencing and Comprehensive Ex Vivo Drug Sensitivity and Resistance Testing

Ashwini Kumar, MRes, Dishaben Rameshbhai Malani, MSc, Bhagwan Yadav, PhD, Matti Kankainen, PhD, Swapnil Potdar, MSc, Mika Kontro, MD, Kimmo Porkka, MD PhD, Olli Kallioniemi, MD PhD, Simon Anders, PhD, Caroline A Heckman, PhD

Blood (2017) 130 (Supplement 1): 1398.

https://doi.org/10.1182/blood.V130.Suppl_1.1398.1398

Published: 2017

Journal Articles

High Amount of PD1+TIM3+ T Helper Cells May Predict Poor Outcome in Adult Acute Lymphoblastic Leukemia

Helena Hohtari, MD, Oscar Brück, Sami Blom, MSc, Riku Turkki, MSc, Antonio Ribeiro, BSc, Marjatta Sinisalo, MD PhD, Panu Kovanen, MD PhD, Olli Kallioniemi, MD PhD, Teijo Pellinen, PhD, Kimmo Porkka, MD PhD, Satu Mustjoki, MDPhD

Blood (2017) 130 (Supplement 1): 3985.

https://doi.org/10.1182/blood.V130.Suppl_1.3985.3985

Published: 2017

Journal Articles

Extensive Immunosuppression in the Acute Myeloid Leukemia (AML) Bone Marrow and Discovery of NK Cells As Biomarker of Superior Survival

Oscar Brück, Sami Blom, MSc, Olli Dufva, BSc, Riku Turkki, MSc, Antonio Ribeiro, BSc, Sanna Siitonen, MD PhD, Panu Kovanen, MD PhD, Olli Kallioniemi, MD PhD, Kimmo Porkka, MD PhD, Teijo Pellinen, PhD, Satu Mustjoki, MD PhD

Blood (2017) 130 (Supplement 1): 3943.

https://doi.org/10.1182/blood.V130.Suppl_1.3943.3943

Published: 2017

Journal Articles

Identification and Clinical Exploration of Individualized Targeted Therapeutic Approaches in Acute Myeloid Leukemia Patients By Integrating Drug Response and Deep Molecular Profiles

Disha Malani, MRes, Ashwini Kumar, MRes, Bhagwan Yadav, PhD, Mika Kontro, MD, Swapnil Potdar, MSc, Samuli Eldfors, MSc, Jani Saarela, Bjørn Tore Gjertsen, Riikka Karjalainen, Tero Aittokallio, Astrid Murumagi, Maija Wolf, PhD, Simon Anders, PhD, Krister Wennerberg, Caroline A Heckman, PhD, Kimmo Porkka, MD PhD, Olli Kallioniemi, MD PhD

Blood (2017) 130 (Supplement 1): 854.

https://doi.org/10.1182/blood.V130.Suppl_1.854.854

Published: 2017

Journal Articles

JAK1/2 and BCL2 inhibitors synergize to counteract bone marrow stromal cell–induced protection of AML

Blood (2017) 130 (6): 789–802.

https://doi.org/10.1182/blood-2016-02-699363

Published: 2017

Includes: Supplemental data

Journal Articles

Immune Cell Profiling in CML Bone Marrow By Multiplex Immunohistochemistry

Brück Oscar, MD, Sami Blom, MSc, Riku Turkki, MSc, Panu E Kovanen, MD PhD, Antonio Ribeiro, Nina Linder, MD PhD, Johan Lundin, MD PhD, Olli Kallioniemi, MD PhD, Teijo Pellinen, PhD, Satu Mustjoki, MD PhD

Blood (2016) 128 (22): 1897.

https://doi.org/10.1182/blood.V128.22.1897.1897

Published: 2016

Journal Articles

BCL2-Inhibitors Target a Major Group of Newly-Diagnosed and Relapsed/Refractory Acute Myeloid Leukemia Ex Vivo

Mika Kontro, MD, Samuli Eldfors, MSc, Muntasir Mamun Majumder, MSc,MPharm, Alun Parsons, MSc, Tea Pemovska, MSc, Olli Kallioniemi, MD PhD, Krister Wennerberg, PhD, Caroline A Heckman, PhD, Kimmo Porkka, MD PhD

Blood (2015) 126 (23): 2462.

https://doi.org/10.1182/blood.V126.23.2462.2462

Published: 2015

Journal Articles

JAK1/2 and BCL2 Inhibitors Synergize to Counter-Act Bone Marrow Stromal Cell-Induced Protection of AML

Riikka Karjalalainen, Tea Pemovska, Muntasir Mamun Majumder, Bhagwan Yadav, Jing Tang, Mika Kontro, Bjørn Gjertsen, MD PhD, Alun Parsons, Minna Suvela, Kimmo Porkka, Tero Aittokallio, Olli Kallioniemi, Krister Wennerberg, Jonathan Knowles, Caroline Heckman

Blood (2015) 126 (23): 867.

https://doi.org/10.1182/blood.V126.23.867.867

Published: 2015

Journal Articles

A Profound Biological Difference of Chronic and Blast Phase Chronic Myeloid Leukemia in Ex Vivo Drug Responses

Paavo Pietarinen, MSc, Tea Pemovska, MSc, Emma I Andersson, MSc, Perttu Koskenvesa, MD, Mika Kontro, MD, Swapnil Potdar, MSc, John Patrick Mpindi, MSc, Olli Kallioniemi, MD PhD, Krister Wennerberg, PhD, Caroline A Heckman, PhD, Satu Mustjoki, MDPhD, Kimmo Porkka, MD PhD

Blood (2014) 124 (21): 3139.

https://doi.org/10.1182/blood.V124.21.3139.3139

Published: 2014

NARROW

Deciphering the Heterogeneity of Acute Myeloid Leukemia through Chromatin Accessibility Profiling

Resistance to FLT3 Inhibitors in FLT3-Mutated AML Is Associated with CD45RA + CD200 - leukemic Cells and Can be Overcome By Combination with SMAC Mimetics

Targeting Mitochondrial Apoptotic Priming State to Personalize Therapy for Relapsed Acute Myeloid Leukemia

Computational Approach Based on Independent Drug Action Identifies Clinically Relevant Combinations for Acute Myeloid Leukemia

Data-Driven Molecular Hallmarks of Acute Myeloid Leukemia: Biological, Prognostic and Therapeutic Implications

Comparison of Data from Fresh and Frozen AML Samples for Functional Drug Testing

High-Throughput Functional Ex-Vivo Drug Testing and Multi-Omics Profiling in Patients with Acute Myeloid Leukemia

Predictive Response Biomarkers for BET Inhibitors in AML

Comparative Analysis of Independent Ex Vivo functional Drug Screens Identifies Predictive Biomarkers of BCL-2 Inhibitor Response in AML

Multi-Parametric Single Cell Profiling Defines Distinct Drug Responses in Healthy Hematological Cell Lineages That Are Retained in Corresponding Malignant Cell Types

Quantitative Multiplex Immunohistochemistry Identifies Immunosuppression in the AML Bone Marrow and NK-Cells As Prognostic Biomarker in Intermediate-Risk Patients

Gene-Drug Interactions in AML Patients Identified By RNA Sequencing and Comprehensive Ex Vivo Drug Sensitivity and Resistance Testing

High Amount of PD1+TIM3+ T Helper Cells May Predict Poor Outcome in Adult Acute Lymphoblastic Leukemia

Extensive Immunosuppression in the Acute Myeloid Leukemia (AML) Bone Marrow and Discovery of NK Cells As Biomarker of Superior Survival

Identification and Clinical Exploration of Individualized Targeted Therapeutic Approaches in Acute Myeloid Leukemia Patients By Integrating Drug Response and Deep Molecular Profiles

JAK1/2 and BCL2 inhibitors synergize to counteract bone marrow stromal cell–induced protection of AML

Immune Cell Profiling in CML Bone Marrow By Multiplex Immunohistochemistry

BCL2-Inhibitors Target a Major Group of Newly-Diagnosed and Relapsed/Refractory Acute Myeloid Leukemia Ex Vivo

JAK1/2 and BCL2 Inhibitors Synergize to Counter-Act Bone Marrow Stromal Cell-Induced Protection of AML

A Profound Biological Difference of Chronic and Blast Phase Chronic Myeloid Leukemia in Ex Vivo Drug Responses

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only